ISMRM25 - Brain Tumors: Metabolism, Spectroscopy & CEST

ISMRM & ISMRT Annual Meeting & Exhibition • 10-15 May 2025 • Honolulu, Hawai'i

ISMRM & ISMRT 2025 Annual Meeting & Exhibition

Digital Poster

Brain Tumors: Metabolism, Spectroscopy & CEST

Back to Meeting Home Back to the Program-at-a-Glance

Brain Tumors: Metabolism, Spectroscopy & CEST

Digital Poster

Neuro

Tuesday, 13 May 2025

Exhibition Hall

08:15 - 09:15

Session Number: D-148

No CME/CE Credit

		Computer Number: 129 2389. Quantitative Analysis of Dynamic CEST Images to Evaluate Pseudoresponse of Bevacizumab Treatment View Presentation Video K. Chai, P. Wang, J. Wu, Z. Zhang, K. Schreck, M. Holdhoff, D. Kamson, L. Blair, J. Laterra, J. Zhou, S. Jiang Johns Hopkins University, Baltimore, United States Impact: This study provides a practical approach for robust and accurate evaluation of Bevacizumab treatment, demonstrating the superiority of CEST imaging in identifying pseudoresponse. It shows potential to complement existing clinical protocols, enabling more precise diagnoses for glioma patients.
		Computer Number: 130 2390. Longitudinal assessment of changes in brain metabolism in the normal-appearing white matter of patients with lower-grade glioma. View Presentation Video Y. Liu, T. Luks, A. Autry, S. Vaziri, L. Cheung, J. Lupo, N. A. Oberheim Bush, S. Chang, J. Villanueva-Meyer, Y. Li UCSF, San Francisco, United States Impact: Results of this study can provide insight into if different treatments can impact a patient’s neurocognitive function that is tied with metabolite profile. The finding can also provide suggestions on when re-treatment is recommended for patients with LrGG.
		Computer Number: 131 2391. A novel approach to the metabolic characterisation of brain tumours: edema-corrected OEF. A hybrid MR-PET study. View Presentation Video A-M Oros-Peusquens, J. Cho, F. Boers, I. Fazli Jaliseh, K-J Langen, N. J. Shah Forschungszentrum Jülich, Jülich, Germany Impact:* A simple and fast acquisition method enables quantitative and metabolic characterisation of brain tumours and can be implemented in large and multicentre patient studies. Applying edema correction makes the properties of underlying tissue accessible, potentially enabling more precise tumour characterisation.
		Computer Number: 132 2392. Quantitative metrics derived from amide proton transfer imaging have improved performance in evaluating glioma subtypes View Presentation Video H. Zhu, X. Zhang, N. Zheng, W. Zhu Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China Impact: The study demonstrates that advanced quantitative metrics derived from APTw imaging have improved ability to diagnose glioma, which may serve as useful imaging biomarkers for glioma evaluation, and facilitate the clinical management and prognosis of glioma patients.
		Computer Number: 133 2393. Fluid suppressed amide proton transfer weighted imaging for distinguishing true progression from treatment response in post-treatment gliomas C-Q Su, J-W Hou, X-C Zhao, S-S Lu The First Affiliated Hospital of Nanjing Medical University, Nanjing, China Impact: FS-APTW imaging offers a more specific characterization of true progression versus treatment response in post-treatment gliomas than APTW imaging.
		Computer Number: 134 2394. Initial experience of characterizing recurrent IDH-mutant astrocytoma using multi-parametric 1H/HP-13C MRI and histopathological analysis View Presentation Video X. A. Xing, A. Autry, T. Luks, M. LaFontaine, D. Nair, J. Lupo, J. Phillips, J. Villanueva-Meyer, H-J Shawn, S. Chang, Y. Li UCSF, San Francisco, United States Impact: This study advances the understanding of glioma metabolism through the integration of novel multi-parametric ¹H/HP-¹³C MRI and tumor histopathological analysis. The insights can enhance precision in characterizing glioma, potentially guiding tailored treatment strategies.
		Computer Number: 135 2395. Amide proton transfer weighted (APTw) imaging for identifying treatment-induced MRI changes in IDH-wildtype glioblastoma at 3 Tesla View Presentation Video I. Krause, T. Zeyen, A. Decker, F. Kroh, S. Regnery, N. Schaefer, J. Weller, J. Keupp, C. Katemann, A. Radbruch, U. Herrlinger, D. Paech University Hospital Bonn, Bonn, Germany Impact: APTw imaging shows promise for clinical use in glioblastoma assessment, particularly for identifying treatment-induced MRI changes. Future prospective studies should evaluate the combination of APTw imaging with other techniques (e.g., DWI and/or perfusion MRI) to further enhance diagnostic accuracy.
		Computer Number: 136 2396. Exploration of the Boundaries of Glioma through T1ρ-weighted Dynamic Glucose-enhanced MR Imaging B. Yin, Y. Zhu, X. Gu, D. Xia, X. Li, Y. Zhao, N. Mei, X. Liu, P-Y Wu, Y. Lu Huashan Hospital, Fudan University, Shanghai, China Impact: T1ρ-DGE MRI acted as a non-invasive visualized imaging tool for the identification of glioma boundaries. T1ρ-DGE MRI holds considerable potential for tumor margin, infiltration, and metabolism of glioma, as well as therapeutic strategies.
		Computer Number: 137 2397. Noninvasive glioma stratification by multiparametric metabolic and microstructural MRI at 3T View Presentation Video C. CADIN, M. DIDIER, L. NICHELLI, B. MATHON, F. SZCZEPANKIEWICZ, M. NILSSON, S. CASAGRANDA, M. ZAISS, F-X LEJEUNE, S. LEHERICY, M. SANSON, F. BIELLE, M. MARJANSKA, F. BRANZOLI Paris Brain Institute - ICM, Inserm U1127, CNRS UMR 7225, Sorbonne Université, UMR S 1127, Equipe labellisée par la Ligue Nationale contre le Cancer, Paris , France Impact: Characterization of novel biomarkers of glioma metabolism and microstructure could enhance diagnostics, deepen understanding of glioma biology, and support an improved glioma stratification. Our PCA model demonstrated high accuracy in distinguishing glioma subtypes defined by WHO 2021 histomolecular classification.
		Computer Number: 138 2398. Improved access and harmonized inline process for 3D spectroscopic MRI to facilitate clinical integration View Presentation Video V. Khalilzad Sharghi, S. Ahn, A. Trivedi, S. Sheriff, R. Guo, K. Chow, A. Maudsley, J. Alger, H. Shim, B. Soher Siemens-Healthineers, Atlanta, United States Impact: Our work brings high-resolution, 3D metabolic imaging into clinical practice for glioblastoma, providing better tools for treatment planning. This advancement could lead to more effective therapies and new research opportunities in brain tumor management, benefiting patients with improved care options.
		Computer Number: 139 2399. Application of APT and MRS in the Grading of Brain Gliomas L. Liu, S. Wan, K. Ai, Y. Zhu, X. Liao Affiliated Hospital of GuiZhou Medical University, Guiyang, China Impact: APT and MRS can predict glioma grade preoperatively. This study suggests that APT and MRS can be used to predict glioma grade preoperatively, providing clinicians with important information for planning treatment strategies and assessing prognosis.
		Computer Number: 140 2400. Towards fully in-line single-voxel MRI spectroscopy for 2HG quantification as an IDH biomarker – can it eventually reach clinical use? View Presentation Video A. Walls, B. Crouch, S. Withey, M-S To, C. Raven, S. Poonnoose, M. Agzarian, A. Dwyer South Australian Health and Medical Institute, Adelaide, Australia Impact: 2HG-MRS achieved with routinely available acquisition in clinical workflow and translated to inline analysis software could promote 2HG as a usable biomarker for IDH status in practice.
		Computer Number: 141 2401. 7T 6,6’-[2H2]-glucose DMI to profile regional metabolism in Glioblastoma View Presentation Video M. Novoselova, C. Graf, J. Karkouri, R. Mair, K. Brindle, C. Rodgers University of Cambridge, Cambridge, United Kingdom Impact: This study establishes methods for ultra-high field deuterium metabolic imaging (7T DMI) to probe glioblastoma metabolism, enabling precise monitoring of metabolic changes. This may enable research to improve therapeutic outcomes, for example by allowing personalised treatment approaches.
		Computer Number: 142 2402. Dose dependency of MRI changes following pre-operative radiotherapy in glioblastoma; volumetric, ASL and APT changes View Presentation Video A. Fothergill, M. Waqar, A. Sovetkina, S. Parikh, D. Higgins, O. Thomas, D. Coope, I. Djoukhadar, G. Borst, L. Parkes The University of Manchester, Manchester, United Kingdom Impact: This study assesses early changes after pre-operative brain irradiation in glioblastoma. We show that hyperintense-FLAIR volume reduces, perfusion increases and MTRasym decreases in a dose-dependent manner within 1-2 days of radiotherapy, providing potentially valuable measures to track radiotherapy response.
		Computer Number: 143 2403. Distinct Amino Acid Profiles in IDH Wild-Type and IDH-Mutant Glioma Subregions: In Vivo 1H MRSI with Optimized Long-TE sLASER at 3T View Presentation Video S. Alcicek, M. W. Ronellenfitsch, J. P. Steinbach, K. J. Weber, V. Prinz, M-T Forster, E. Hattingen, U. Pilatus, K. J. Wenger Goethe University, University Hospital Frankfurt, Frankfurt am Main, Germany Impact: We used optimized long-TE-sLASER MRSI at 3T and automated brain tumor segmentation to evaluate distinct amino acid profiles in glioma molecular subtypes. Our study highlights the necessity for separate (e.g., glutamate-glutamine, glycine-myoinositol) and tumor-subregion-specific quantification of metabolites.
		Computer Number: 144 2404. Brain Metabolic Alterations in Adult Survivors of Childhood Brain Tumours Mapped through Multi-Voxel 1H MRS View Presentation Video S. Helsper, K. Bullens, C. Sleurs, A. Radwan, S. Sunaert, J. Lemiere, S. Jacobs, U. Himmelreich KU Leuven, Leuven, Belgium Impact: Multi-voxel ¹H MR spectroscopy combined with corresponding anatomical MRI can provide insight into metabolic brain alterations. Our study suggests alterations related to axonal loss in adults treated for childhood brain tumours, offering insights into long-term effects of early-life cancer therapies.

Similar Session(s)

Back to Meeting Home Back to the Program-at-a-Glance

The International Society for Magnetic Resonance in Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.